Abstract:Objective Oncogenic Kras-activated robust Mek/Erk signals phosphorylate to the tuberous sclerosis complex (Tsc) and deactivates mammalian target of rapamycin (mTOR) suppression in pancreatic ductal adenocarcinoma (PDAC); however, Mek and mTOR inhibitors alone have demonstrated minimal clinical antitumor activity.Design We generated transgenic mouse models in which mTOR was hyperactivated either through the Kras/Mek/Erk cascade, by loss of Pten or through Tsc1 haploinsufficiency. Primary cancer cells were isolated from mouse tumours. Oncogenic signalling was assessed in vitro and in vivo, with and without single or multiple targeted molecule inhibition. Transcriptional profiling was used to identify biomarkers predictive of the underlying pathway alterations and of therapeutic response. Results from the preclinical models were confirmed on human material.Results Reduction of Tsc1 function facilitated activation of Kras/Mek/Erk-mediated mTOR signalling, which promoted the development of metastatic PDACs. Single inhibition of mTOR or Mek elicited strong feedback activation of Erk or Akt, respectively. Only dual inhibition of Mek and PI3K reduced mTOR activity and effectively induced cancer cell apoptosis. Analysis of downstream targets demonstrated that oncogenic activity of the Mek/Erk/Tsc/mTOR axis relied on Aldh1a3 function. Moreover, in clinical PDAC samples, ALDH1A3 specifically labelled an aggressive subtype.Conclusions These results advance our understanding of Mek/Erk-driven mTOR activation and its downstream targets in PDAC, and provide a mechanistic rationale for effective therapeutic matching for Aldh1a3-positive PDACs.

Supplementary Figures 1-4 from <i>Pten</i> Inactivation Accelerates Oncogenic <i>K-ras</i>–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Supplementary Tables 1-2 from <i>Pten</i> Inactivation Accelerates Oncogenic <i>K-ras</i>–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Supplementary Table 3 from <i>Pten</i> Inactivation Accelerates Oncogenic <i>K-ras</i>–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Data from <i>Pten</i> Inactivation Accelerates Oncogenic <i>K-ras</i>–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Supplementary Figures 1-3 from Genetic Background Controls Tumor Development in <i>Pten</i>-Deficient Mice

Supplementary Figure 4 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Supplementary Figure 1 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Figure S2 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Supplementary Materials and Figure Legends 1-4 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Supplementary Figure 2 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Supplementary Figure 3 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Supplementary Figure Legends 1- 4 from PTEN Loss Accelerates <i>Kras</i><sup><i>G12D</i></sup>-Induced Pancreatic Cancer Development

Supplementary Figures 1-7 from <i>Pten</i> Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer.

Supplementary Figure from Loss of MLL Induces Epigenetic Dysregulation of Rasgrf1 to Attenuate Kras-Driven Lung Tumorigenesis

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Mutationally Activated K-ras 4A and 4B Both Mediate Lung Carcinogenesis.

The Impact of K-rasG12D Activation and p53 Loss upon Tumorigenesis

Supplementary Figures 1-4 from &lt;i&gt;Pten&lt;/i&gt; Inactivation Accelerates Oncogenic &lt;i&gt;K-ras&lt;/i&gt;–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Supplementary Tables 1-2 from &lt;i&gt;Pten&lt;/i&gt; Inactivation Accelerates Oncogenic &lt;i&gt;K-ras&lt;/i&gt;–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Supplementary Table 3 from &lt;i&gt;Pten&lt;/i&gt; Inactivation Accelerates Oncogenic &lt;i&gt;K-ras&lt;/i&gt;–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Data from &lt;i&gt;Pten&lt;/i&gt; Inactivation Accelerates Oncogenic &lt;i&gt;K-ras&lt;/i&gt;–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Supplementary Figures 1-3 from Genetic Background Controls Tumor Development in &lt;i&gt;Pten&lt;/i&gt;-Deficient Mice